C-MGFMTNF Pharmaceuticals (was MyMD)
biotech pharmaceuticals, MYMD-1, Supera-CBD
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MGFM
C-MGFMC-MGFMbiotech pharmaceuticals, MYMD-1, Supera-CBD
0-100 chain-logic scale · 15 dimensions · scored on public evidence
TNF Pharmaceuticals states that it is developing groundbreaking therapies to fight chronic disease and improve quality of life, with a focus on transforming how aging and age-related diseases, autoimmune diseases, and chronic pain, anxiety, and sleep disorders are targeted. The company presents its strategy as advancing synthetic therapeutics, including MYMD-1 and Supera-CBD, and explicitly says its team is working on what it describes as the first drug being designed to significantly increase human lifespan.
SourceTNF Pharmaceuticals presents itself as a company "leading the charge in biotech pharmaceuticals," centered on pharmaceutical research, clinical trials, and its product pipeline, while also stating that it has secured exclusive global rights to a computing accelerator for cryptocurrency and blockchain applications and intends to change its name to reflect that new venture.
SourceTNF Pharmaceuticals states that it is developing novel therapeutics to fight chronic disease and improve quality of life, with a focus on transforming how aging and age-related diseases, autoimmune diseases, and chronic pain, anxiety, and sleep disorders are targeted. The company also states that its team works with academic founders and key opinion leaders to identify synthetic therapeutics, including what it describes as the first drug being designed to significantly increase human lifespan.
Source